Deals
GSK and Hansoh Pharmaceutical’s antibody-drug conjugate success validates their partnership, one of the many deals in which Big Pharma has tapped a China company for promising cancer candidates.
FEATURED STORIES
The total of 52 mergers and acquisitions for the first half of 2026 reflects what analysts, industry watchers and executives are saying over and over: M&A is back.
Dealmaking across biopharma is shifting dramatically as the SEC rolls out new regulations to ease burdens on newly public companies and antitrust review is replaced by drug pricing as the policy concern du jour.
Dual and even triple or quadruple track processes have come roaring back in 2026 thanks to a glut of M&A that has refilled investors’ wallets. Big Pharma is being put on notice that time is critical if they want to acquire.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Investors are salivating at the possibility of a hot merger-and-acquisition market in 2018.
Shares of Strata Skin Sciences are up more than 12 percent this morning after the company announced it will explore strategic options up to and including a sale of the company in order to enhance stockholder value.
Perrigo is expected to face competition from Swiss food giant Nestle and the private equity owners of German drug firm Stada.
As part of a portfolio update, Altas Ventures noted that Raze Therapeutics, a biotech launched in 2014, has closed its doors.
Harpoon’s former CEO also hinted at possible growth at the office, including new hires for engineering and clinical team members.
A look at what three ex-Genentech employees have accomplished at Denali so far.
Gilead was interested in Cell Design Labs for its technology around bi-specific antigen recognition and its “Throttle” technology.
This year wasn’t big for mergers and acquisitions in biopharma, particularly compared to 2015 and 2016.
As Sanofi grapples with the fallout from its Dengue vaccine, the termination of its late-stage C. diff vaccine and falling short of its third quarter expectations, company investors are getting antsy for some good news.
Dart will close its doors on Feb. 9 due to poor progress on its therapeutic goals and little return on hundreds of millions of dollars in R&D.